

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Set of samples 1																							
(81) Digoxin					10																		
Samples and groups		[nmol/L]																					
Sample A1			2,05	0,43	21	10																	
(4) LIA, ILMA			2,01	0,56	28	8																	
Other					2	0																	
Sample B1			2,44	0,52	21	10																	
(4) LIA, ILMA			2,42	0,66	27	8																	
Other					2	0																	
(82) Theophylline					4																		
Samples and groups		[µmol/L]																					
Sample A1			111	13	11	4																	
Other					4	0																	
Sample B1			66,7	6,5	9,8	4																	
Other					4	0																	
(84) Phenobarbital					5																		
Samples and groups		[µmol/L]																					
Sample A1			65,7	5,4	8,2	5	CVP	64,5	2,2	20%	51,6	77,4	5	5	100%								
Other					5	0							5										
							4x 4, 1x 6																
Sample B1			97,0	7,2	7,4	5	CVP	95,3	2,9	20%	76,2	115	5	5	100%								
Other					5	0							5										
							4x 4, 1x 6																
(85) Phenytoin					3																		
Samples and groups		[µmol/L]																					
Sample A1			63,9	3,0	4,7	3	CVP	61,8	1,5	20%	49,4	74,2	3	3	100%								
Other					3	0							3										
							1x 4, 2x 6																
Sample B1			55,4	3,9	7,0	3	CVP	53,6	0,95	20%	42,8	64,4	3	3	100%								
Other					3	0							3										
							1x 4, 2x 6																
(86) Carbamazepin					9																		
Samples and groups		[µmol/L]																					
Sample A1			8,82	0,42	4,7	9	CVP	9,32	0,30	20%	7,45	11,2	9	9	100%								
Other					9	0							9										
							3x 2, 4x 4, 2x 6																
Sample B1			25,2	2,2	8,8	9	CVP	26,2	0,58	20%	20,9	31,5	9	9	100%								

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(86) Carbamazepin	[µmol/L]				9							9	9	100%									0
Samples and groups																							
Sample B1		25,2	2,2	8,8	9		CVP	26,2	0,58	20%	20,9	31,5	9	9	100%								0
Other					9	0							9										
								3x 2, 4x 4, 2x 6															
(88) Valproic acid	[µmol/L]				10								10	9	90%								0
Samples and groups																							
Sample A1		222	36	16	10		CVP	216	4,5	20%	172	260	10	9	90%								0
(4) LIA, ILMA		203	32	16	5	0							5										
Other					5	0							5										
								2x 2, 3x 6															
Sample B1		537	79	15	10		CVP	536	9,0	20%	428	644	10	9	90%								0
(4) LIA, ILMA		517	92	18	5	0							5										
Other					5	0							5										
								2x 2, 3x 6															
Set of samples 2																							
(89) Amicacin	[µmol/L]				1								1	1	100%								0
Samples and groups																							
Sample A2		4,62			1		CVP	4,6	0,44	42%	2,66	6,54	1	1	100%								0
Other					1	0							1										
								1x 2															
Sample B2		21,2			1		CVP	24,9	0,70	20%	19,9	29,9	1	1	100%								0
Other					1	0							1										
								1x 2															
(90) Gentamicin	[µmol/L]				5								5	5	100%								0
Samples and groups																							
Sample A2		12,4	1,3	11	5		CVP	13	0,55	31%	8,97	17,1	5	5	100%								0
Other					5	0							5										
								4x 4, 1x 6															
Sample B2		9,37	0,35	3,7	5		CVP	9,61	0,38	31%	6,63	12,6	5	5	100%								0
Other					5	0							5										
								4x 4, 1x 6															
(92) Vankomycin	[µmol/L]				6								6	6	100%								0
Samples and groups																							
Sample A2		24,4	1,5	6,3	6		CVP	25	1,0	28%	18	32	6	6	100%								0
Other					6	0							6										
								4x 4, 1x 6, 1x 99															
Sample B2		10,6	1,0	9,9	6		CVP	10,8	0,42	28%	7,77	13,9	6	6	100%								0
Other					6	0							6										
								4x 4, 1x 6, 1x 99															
(93) Methotrexate	[µmol/L]				2								2	1	50%								0
Samples and groups																							
Sample A2		11,2	2,8	25	2		CVP	9,13	0,80	30%	6,39	11,9	2	1	50%								0
Other					2	0							2										
								2x 4															
Sample B2		0,403	0,01	2,5	2		CVP	0,421	0,022	30%	0,294	0,548	2	2	100%								0
Other					2	0							2										
								2x 4															

